Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beamion 44
2025-523567-38-00Phase 2Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of zongertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Discontinuation or prolonged interruption of zongertinib due to treatment-related adverse events in the first 2 cycles. Planned start Jun 2026; status: authorised.
02
Drugs
zongertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-523567-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523567-38-00.